Prof. Qian Chu 褚倩
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of thoracic tumors (lung, esophageal, mediastinal, pleural, thymic) using radiotherapy, targeted therapy, immunotherapy, and chemotherapy. Also provides supportive and palliative care.
Dr. Chu is a Chief Physician, Professor, and Doctoral Supervisor, serving as Deputy Director of the Thoracic Oncology Department. Dr. Chu earned a medical doctorate from Tongji Medical College, Huazhong University of Science and Technology (1994–2004) and completed postdoctoral work at Johns Hopkins Hospital in the United States (January 2011–September 2012).
Professional roles
- Member, Immunotherapy Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Non-Small Cell Lung Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Young Member, Chinese Anti-Cancer Association
- Vice Chair, Lung Cancer Expert Committee, Hubei Clinical Oncology Society
Name order: in Chinese the family name comes first (Chu Qian). Papers usually list the name as Qian Chu or Chu Q.
Selected publications
206 papers on PubMed matched by name and affiliation; 37 as first or senior author since 2016. Most recent first- or senior-author papers:
- EClinicalMedicine, 2026 (senior author): Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial. PubMed 42964339
- iScience, 2026 (senior author): ONC201 enhances the radiosensitivity of small-cell lung cancer via inhibition of the FAK signaling pathway. PubMed 42643276
- Clin Transl Med, 2026 (senior author): Targeting the CTBP1-CETP axis overcomes ferroptosis resistance in non-small cell lung cancer by altering lipid accumulation. PubMed 42515937
- J Transl Med, 2026 (senior author): Glycolytic reprogramming in cancer: tumour cell metabolism, immune modulation, and therapeutic opportunities. PubMed 42321806
- J Immunother Cancer, 2026 (senior author): HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence. PubMed 42320983
- Chin Med J Pulm Crit Care Med, 2026 (senior author): Molecular mechanisms and therapeutic targets in lung cancer-nerve crosstalk. PubMed 42396193
- Discov Oncol, 2026 (senior author): Peripheral blood IFN-γ-producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor-based therapy. PubMed 42258128
- Thorac Cancer, 2026 (senior author): Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China. PubMed 42246683
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion